Oncology and Translational Medicine

Aims & Scope

Oncology and Translational Medicine (OTM) is an international, open-access, peer-reviewed academic journal that aims to promote research in oncology and translational medicine as well as levels of service in clinical practice.

It publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis, and treatment of human cancers with the overall goal of improving the clinical care of oncology patients.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Immunology and Microbiology and Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Immunology and Microbiology and Medicine, ensuring accessibility and quality in research dissemination.

This journal does not charge a mandatory Article Processing Charge (APC). However, optional open access publication may incur fees based on the publisher’s policies.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Nanomaterials for refining tumor microenvironment and enhancing therapy in head and neck squamous cell carcinoma: a review

  Citation: 18

  Authors: Kaifeng, Ruibiao, Ruifeng, Mengli, Yunpeng, Wei, Kelong

• Updates of the NCCN guidelines for non-small cell lung cancer

  Citation: 14

  Authors: Liu

• Optical molecular imaging in cancer research: current impact and future prospect

  Citation: 11

  Authors: Yinuo, Zihan, Yuting, Xiaofan, Tian, Xiangyi, Mingfu

• Advancements in conventional cancer therapy combined with immunotherapy

  Citation: 7

  Authors: Hongxia, Songyan, Chunbo, Zhida

• Development of therapeutic cancer vaccines using nanomicellar preparations

  Citation: 7

  Authors: Yan, Wen-Feng, Wei

• Advances in immunotherapy and targeted therapy for pancreatic cancer

  Citation: 6

  Authors: Xiangyan, Xiaohui, Shengli, Zaozao

• Analysis of the intestinal flora in patients with primary liver cancer*

  Citation: 6

  Authors: Chengcong, Guoxin, Huizhe, Gaishuang, Xiong, Xiao

• Exploring combination therapy centered on targeted immunotherapy for advanced hepatocellular carcinoma: a beacon of hope

  Citation: 6

  Authors: Yanbin, Yuqi, Hong, Jing, Anping, Hong, Xianglin, Hua, Yanmei

• Tumor-infiltrating T-Lymphocyte immunity-related immune tolerance and anti–programmed cell death protein 1/ligand of programmed cell death protein 1 therapy for advanced hepatocellular carcinoma

  Citation: 5

  Authors: Lingzhen, Zongren, Yang, Xiaomeng, Huojun, Zhuoying

• Comprehensive insights into systemic therapy for the whole-course management of hepatocellular carcinoma

  Citation: 5

  Authors: Jiayun, Kai, Leida, Kuansheng